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Diabetes Mellitus (DM) is a chronic disease characterized by hyperglycemia, as a result of abnormal insulin
production, insulin function, or both. DM is associated with systemic complications, such as infections, neuropathy
and angiopathy, which involve the genitourinary tract. The three most significant urologic complications include:
bladder cystopathy, sexual dysfunction and urinary tract infections.
Almost half of the patients with DM have bladder dysfunction or cystopathy, which can be manifested in women
as hypersensitivity (in 39–61% of the diabetic women) or neurogenic bladder. In males it can be experienced as
lower urinary tract symptoms (in 25% of diabetic males with a nearly twofold increased risk when seen by age
groups). Additionally, an increased prostate volume affects their micturition as well as their urinary tract.
Involving sexual dysfunction in women, it includes reduced libido, decreased arousal, clitoral erectile dysfunction
and painful or non-sensitive intercourse; and in diabetic males it varies from low libido, ejaculatory abnormalities
and erectile dysfunction. Globally, sexual disorders have a prevalence of 18–42%. Erectile dysfunction is ranked as
the third most important complication of DM. Urinary tract infections are observed frequently in diabetic patients,
and vary from emphysematous infections, Fournier gangrene, staghorn infected lithiasis to repetitive bacterial cystitis.
The most frequent finding in diabetic women has been lower urinary tract infections. Because of the high incidence of
obesity worldwide and its association with diabetes, it is very important to keep in mind the urologic complication
associated with DM in patients, in order to better diagnose and treat this population.
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The high incidence of urologic complications associated
with diabetes mellitus (DM) is an increasing health con-
cern throughout the entire world. Especially, if we con-
sider the high incidence of obesity worldwide, being the
United States and Mexico the countries with major inci-
dence (Rull et al. 2005).
DM is a group of metabolic diseases characterized by
hyperglycemia caused by a diminished insulin secretion,
insulin effect, or both. This chronic hyperglycemia is as-
sociated with systemic long-term damage, dysfunction,
and failure of several tissues. DM is classified into many
categories, being the most frequent: type 1, type 2 and ges-
tational diabetes (American Diabetes Association 2011).* Correspondence: elena.soto01@upaep.mx
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reproduction in any medium, provided the origUrologic complications in patients involve the endo-
thelial and neural damage associated systemically, which
involve the genitourinary tract. To simplify this review
we divided them into three groups: lower urinary tract
dysfunction, sexual dysfunction, and urinary tract infec-
tions. It is noteworthy to mention that all of them have
a significant negative effect on the quality of life of dia-
betic patients, as well as life threatening complications.Urologic complications in patients with diabetes
Bladder dysfunction
Almost half of male and female patients with DM suffer
from different degrees of bladder cystopathy. Bladder
dysfunction (BD) can involve different degrees and com-
binations of diminished bladder filling sensation and
poor contractility, which results in an increased post
void residual urine, predisposing to infections, lithiasis
or renal damage.r. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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diabetes have reported bladder hypersensitivity or blad-
der instability as the most frequent finding, ranging from
39–61% of the patients (Golbidi and Laher 2010). BD
was present in 74.07% of men (DC, 50%; bladder outlet
obstruction OO, 25%; detrusor overactivity, 25%) and in
59.26% of diabetic women (Kebapci et al. 2007). Add-
itionally, recent evidence suggests that lower urinary tract
symptoms (LUTS) may occur more frequently among
men with diabetes, with an estimated 25% to nearly
twofold increased risk of LUTS in men with diabetes.
There are a wide variety of symptoms which vary from
urge incontinence (risk of 40% to 80%) to the most se-
vere expression of overflow incontinence (80% increased
risk) (Brown et al. 2003). Therefore, it is obvious that this
pathology represents a combination of both, storage and
voiding abnormalities.
Bladder symptoms are divided in irritative and ob-
structive. The first ones can be presented as an over-
active bladder syndrome, which involves an overexcited
detrusor muscle, which cause urgency, pollakiuria, noc-
turia and urgency incontinence. Obstructive symptoms
are related to a pseudo-obstructive bladder, which repre-
sent a late phase of the diabetic neuropathy and are
characterized by low uroflowmetry, high postmictional
residue, and a hypotonic bladder in the cystometry. The
last one reflects a myogenic alteration of the neuronal
and microvasculature. These pseudo-obstructive symp-
toms include a decreased size and strength of the void-
ing flow, terminal dribbling, decreased sensation of a full
bladder and high post void residual urine (very similar to
those seen in the benign prostate hyperplasia) (Daneshgari
et al. 2009; Liu and Daneshgari 2006).
During the early stage of diabetic cystopathy, there is
an increase in bladder storage capacity, which affects its
compliance or ability to adapt its fullness. Thus, dimin-
ishing its contractility, and increasing the post void re-
sidual volume. It has also been noticed that in an effort to
counteract against these changes, there is certain bladder
hypertrophy which causes further bladder instability in its
contractions because of collagen deposits, making the
tightening of the detrusor muscle ineffective. All of
these deviations in the bladder physiology and function
have been reproduced with cystometry in diabetic rats,
which shows a bladder with increased capacity and
raised threshold for initiation of micturition reflex. When
sacrificed diabetic rats have bladder hypertrophy resulting
in approximately a doubling of bladder weight as an effect
of abnormally prolonged diuresis (Liu and Daneshgari
2006). With this in mind, it has been proposed that the as-
sociated increase in diuresis due to DM with the neural
and endothelial damage, can collectively lead to the de-
trusor muscle hypertrophy in an attempt to adapt it. The
bladder hypertrophy could also cause an increase in theoxidative stress, associated with further damage to the
muscle (Satriano 2007), or it could be induced by an
axonal transport deficiency in the NGF (neural growth
factor) which plays an important role in inducing diabetic
neuropathy, in diabetic rats (decreased NGF levels in the
bladder are associated with bladder dysfunction). Bladder
tissue remodeling is also associated with down regulation
of TGF (tissue growth factor) and collagen mRNA levels,
which produce an increase in elastin synthesis. Bladder
compliance in DM patients is increased, as a result not
only from a reduction in collagen synthesis but also from
an increased in elastin synthesis (Gray et al. 2008).
The micturition reflex is the neural stimulus con-
trolled by M2 and M3 receptors. In DM has been found
an increased number of muscarinic receptors in the
urothelium, increasing the sensory nerve activity and af-
fecting the detrusor contraction, causing further bladder
dysfunction (Cheng et al. 2007). Also the abnormalities
in the Ca++ and K+ channels that further increase the
overactive detrusor muscle. When cells are constantly
exposed to hyperglycemia for long periods of time, it
can cause an accumulation of oxidative stress products;
which plays an important role in nerve damage, that
cause cystopathy and erectile dysfunction (Beshay and
Carrier 2004). Cystopathy has been demonstrated in a
rabbit model with alloxan induced diabetes, in which
Changolkar et al. observed an aldose reductase over ex-
pression and an increment in lipid peroxidation products,
resulting in diminished detrusor contractility. Further-
more, this overexpression promotes the production of
sorbitol, increasing glucose through the polyol path-
way, these changes lead to myopathy which causes incom-
plete voiding during micturition. (Changolkar et al. 2005).
In women with DM the insulin treatment increases
the risk of urge incontinence, compared with the use of
metformin which has shown that it does not have any
effect in the incontinence (Brown et al. 2004, Jackson
et al. 2004).
Concerning the different types of incontinence, they
are managed according to their etiology. In the asymp-
tomatic diabetic patient, it is advisable to instruct them
on schedule voiding and the association of external
compression of the pelvic area to optimize their blad-
der emptying.
The first line of treatment of urge incontinence (result
of a hyperactive detrusor) is an oral muscarinic selective
anticholinergic such as oxibutynin, tolterodine or solife-
nacin. In certain individuals, infiltration of the detrusor
muscle with botulinum toxin has proven to diminish
their urge incontinence. If severe urge incontinence is
not resolved with muscarinic selective anticholinergics,
then a surgical approach could be offered, which includes:
bladder denervation, myomectomy (to cause a pseudodiver-
ticulum) and bladder augmentation with ileal cystoplasty.
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post-void volume with its association with urinary tract
infections. In certain males with added bladder outlet
obstruction due to prostate enlargement, transurethral
surgery could be considered. Moreover, there is a new
drug 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-
phenylethyl] amino}ethyl) named mirabegron a β3-
adrenergic agonist. It has been shown that simulating
this receptor contributes to increase the urine storage,
through direct relaxation of the detrusors smooth muscle
(Aizawa et al. 2012); with a rapid onset of action, providing
a rapid relief in the symptoms of the patient and has an ex-
cellent tolerability profile, thus helping patients persist with
the treatment (Chapple et al. 2014). Although there is little
real evidence about its effectiveness and side effects.
Finally, in patients with a neurogenic bladder with
overflow incontinence, the first line of treatment is a
cholinergic treatment with bethanechol to increase the
bladder contractility and better emptying. In case of
empty failure, frequent clean intermittent catheterization
is the best choice to avoid long term indwelling catheter
because of the risk of increased infection rate, lower
urinary tract lithiasis and epidermoid bladder carcinoma
(Deli et al. 2013).
Prostatic enlargement
DM is frequently associated with benign prostatic hyper-
plasia (BPH), because of the age of incidence. Additionally,
bladder dysfunction, could cause an increased sympathetic
nerve activity and the vascular damage, resulting in fur-
ther hypoxia in the bladder and prostate, associated
with an abnormal cell proliferation, which added re-
sults in an increase in the lower urinary tract symp-
toms (Berger et al. 2005).
One of the potential explanations of the presence of
BPH in diabetic patients, involves the insulin-like growth
factor (IGF). In type-2 diabetes, β-cells secrete greater
concentrations of insulin, the resulting hyperinsulinemia
which stimulates IGF production; in mouse models of
hypoinsulinemia had a significant prostate growth (Ikeda
et al., 2000; Vikram et al., 2010). The type 1 diabetes
models do not show an effect on prostate growth (Yono
et al., 2005; Yono et al., 2008). The possible mechanism
is the high degree of homology between insulin receptor
and IGF receptor (Ullrich et al., 1986), it has been de-
scribed that exist a cross-activity of their receptors
(Frasca et al., 2008; Liu 2007). So the insulin may cause
the prostatic growth during type-2 diabetes by activating
the IGF receptor.
The treatment for patients with BPH depends of the
prostate volume. Patients with a small prostate, alpha-1
blockers are the first line of treatment (non selective:
doxazosin and terazosin; and uroselective: tamsulosin,
alfuzosin and silodosin). In patients with BHP and erectiledysfunction the use of daily phosphodiesterase type 5 in-
hibitors have been shown to reduce both symptoms. In-
dividuals with an enlarged prostate (over 40gr) the use
of combined alpha-1 blockers with an alpha 5 reductase
inhibitor (finasteride (selective) and dutasteride (non-
selective) making it more effective) is recommended,
in order to diminish the prostate volume in the long
term with the faster effect on bladder neck relaxation.
Another newly recognized group of patients are the
ones with only detrusor hyperactivity, which should be
treated with muscarinic selective anticholinergic drugs
as mentioned above in the urge incontinence section.
And finally, in case that all of the above have failed or
there is an indication for surgery, the surgical approach
should be done, being the gold standard the trans-
urethral resection of the prostate (with bi-polar, mono-
polar or laser energy) (Mcvary et al. 2011).
Urethral tightening
Endothelial dysfunction and nitric oxide (NO) deficiency
are among the most important factors in the develop-
ment of diabetic complications, and the lower urinary
tract is also affected. NO is partially responsible of the
outflow obstruction by affecting the relaxation of the ur-
ethral sphincter, causing afferent neurons to be hyper-
excitable in the progression of diabetes (Torimoto et al.
2004). Recent evidence has shown that the increased risk
of an overactive bladder in diabetic patients is closely re-
lated to the peripheral nerve irritation, and if this occurs
in males and females, then this should be taken into ac-
count when analyzing bladder dysfunction and prostate
enlargement (Wei-Chia 2009). All of the above explains
why diabetic patients can be successfully treated for BPH
symptoms and erectile dysfunction with daily oral phospho-
diesterase 5 inhibitors (currently the only available drug is
5 mg Tadalafil).
Sexual dysfunction
Sexual dysfunctions are defined as the inability to achieve
or maintain an adequate sexual response to complete a
sexual encounter or intercourse resulting in a satisfactory
orgasmic sensation; it affects diabetic males and females
patients, and includes diminished libido, orgasmic abnor-
malities and erectile dysfunction. The incidence of sexual
dysfunction in healthy males is up to 32% compared to
46% in type II diabetic males (Vickers and Wright 2004).
In females it is harder to diagnose because of the multiple
confusing factors that have an effect. However, it has been
proposed that in healthy women, 25-63% have some
sort of sexual dysfunction (Kammerer-Doak 2012), and
in women with type 1 DM they have a prevalence of
sexual dysfunction of 71% and of 42% in women with
type 2 DM (Enzlin et al. 2002; Owiredu et al. 2011).
These abnormalities involve a group of alterations that
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reduced desire, decreased arousal, orgasmic abnormal-
ities and painful intercourse. In diabetic women, clit-
oral erection is also affected, however it is one of the
multiple components of sexual function; this is why its
treatment with oral inhibitors of phosphodiesterase- 5
inhibitors does not completely solve sexual dysfunction
in women. In DM it is one of the most frequent chronic
complications that needs further research because its inci-
dence, pathophysiology and treatment are partially under-
stood and unfortunately in clinical practice very rarely
questioned and treated (Doruk et al. 2005).
It is important to consider certain risk factors that fur-
ther affect diabetic men and women such as: age, neuro-
genic and vascular complications, medications (Table 1),
obstetric history, as well as their association with: cancer,
cardiovascular disease, neurological conditions and hys-
terectomy, among others.
Erectile dysfunction
Erectile dysfunction (ED) is described as a long term
persistent inability to achieve or maintain an adequate
rigid erection in order to have a satisfactory sexual en-
counter. ED is the third most frequent complication of
diabetes and is considered as one of the most important
complications that affects their quality of life (Latini
et al. 2003). ED manifests after 10 to 12 years since the
onset of DM and commonly occurs earlier in males with
DM (10 to 15 years) because of diabetic endothelial and
neural damage associated with persistent high serum
glucose levels, in fact Sun et al. propose that if males
younger than 45 have ED it could be an early sign of
DM (Sun et al. 2007).
It has been proven in experimental animal models that
central and peripheral neuropathy, endothelial dysfunc-
tion and impaired neurotransmission are the underlying
factors in the pathogenesis of diabetic ED.
Men with erectile dysfunction have a diminished re-
sponse causing less relaxation of the vascular smoothTable 1 Medications that increase sexual dysfunction in
the diabetic patient
Diseases Medications
Cardiovascular disease Antihypertensive, B blockers
Chronic pulmonary disease Methyldopa, clonidine, reserpine
Chronic renal insufficiency Thiazide diuretics, spirinolactones
Prostatic enlargement Phenothiazines, butyrophenones, tricyclic
antidepressants, selective serotonin
reuptake inhibitors
Prostate cancer Estrogens, anti-androgens, LH antagonist.
Hypogonadism Cimetidine, metoclopramide
Thyroid desease Alcohol
Cancer of any origin Radiotherapy, chemotherapymuscle tissue, due to the deficient production of NO
in the non adrenergic- non cholinergic neurons and in
the endothelium (Morano 2003). There is also a sig-
nificant accumulation of advanced glycation products
(Seftel et al. 1997) with an altered expression of argi-
nase, which is a competitor with the nitric oxide synthase
for its substrate L-arginine (Bivalacqua et al. 2001). All of
these factors cause a tendency towards vasoconstrictors,
such as phenylephrine and endotheline-1, causing the lack
of vasodilatation that is the cause of penile erection.
There are several mechanisms that play an important
role in the pathophysiology of diabetic ED, which in-
clude: an increased flux in the hexosamine and polyol
pathway, activating the protein kinase and the intracellu-
lar accumulation of advanced glycation products. The
polyol pathway, forms sorbitol, by action of the aldose
reductase; this sorbitol accumulates inside the cell, caus-
ing a diminished myo-inositol concentration, which is a
precursor of the phosphatidylinositol, a molecule needed
for the membrane Na-K ATPase bomb to function. The
sorbitol increase causes a constant damage to the per-
ipheral nerves. The Advanced glycation products AGE’s
are produced by the glycation of proteins, the union of
the AGE to their macrophages receptors can lead to
cytokine release (Brownlee 2001, Neves 2013). It has
been proposed that AGE’s produces free radicals, react-
ive oxygen species that produce oxidative cell damage,
cGMP decrease, NO extinction and decrease in the
cavernosal smooth muscle relaxation (Cartledge et al.
2001). McVary and cols argue that not only does periph-
eral neuropathy have a major role, but also the spinal
sexual reflexes. In the study of diabetes induced model in
rats, they showed a diminished copulatory behavior and
penile reflexes after 4 to 12 months (Mcvary et al. 1997).
Concerning the vascular component, the endothelial
damage also participates in a direct form, because the ar-
terial inflow is diminished in diabetic patients in compari-
son to healthy males. This has been proven microscopically
with a reduced diameter and deficient morphology of vas-
cular components (Grant et al. 2013). The contraction of
cavernosal smooth muscle cells is affected by hypergly-
cemia, with an increased forced response to vasocon-
strictors. This could be partially explained because of a
sensitization pathway in the protein Kinase C and the
Rho A-Rho kinase Ca2+ pathways, which could cause
a tendency towards a flaccid stage and modify the re-
sponses of nitric oxide (NO) (Chitaley et al. 2001). All
of the above should be taken into account with the
added factors that impact erectile function that include
apoptosis or atrophy of the cavernous smooth muscle
due to a diminished expression of bcl2, intracellular
release of Ca2+, increased connective tissue prolifera-
tion due to tumor growth factor beta causing fibrosis
and a deficient response to NO in the cavernous and
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endothelial levels of nitric oxide synthetase (Burchardt
et al. 2000). In brief, there are several components that
take place in the endothelial and neural damage in the
periphery and central nervous system, which globally
impact on erections in patients with DM.
To determine the degree of ED in DM patients there
is the International Questioner for Erectile Function,
that helps to determine the degree of ED, and evaluate
the progression or response to the medical treatment. In
certain cases, in which a more precise evaluation of the
vascular flows is needed, an echo-Doppler could be used
to determine the cavernous artery flux and morphology.
Some research papers have proposed the use of noctur-
nal penile tumescence test and electro-stimulation stud-
ies to determine the damage of the myelinated sensory
fibers of the pudendal somatosensory fibers in the lower ex-
tremity as well as unmyelinated fibers (Dean and Lue 2005).
It is very important to discuss the different treatment
options with the patient and their partners in order to
better understand their needs, worries and perspectives
of their treatment. The first line of treatment is oral
medications, followed by intracavernosal injection and
finally with penile prosthesis surgery.
Sildenafil, tadalafil, udenafil and vardenafil are the four
oral agents used for the ED treatment. They all share the
same mechanism of action, which involves the hydrolysis
of guanosine monophosphate to guanosine 5′ – mono-
phosphate, diminishing it, then there is an increase in
the relaxation of the cavernosal smooth muscle mediated
by NO, increasing the blood flow in the corpus cavern-
osum resulting in penile erection. Boulton et al. demon-
strated a significant improvement in the sexual function
of men with type 2 DM (in the rigidity maintenance and
satisfaction of the erection reported by the patient and
their partner) (Boulton et al. 2001). Nevertheless, studies
demonstrate that type 5 phosphodiesterase inhibitors
are not as effective in men with ED without diabetes
(Carson 2003).
The other difference in the several available drugs is
the time and the length of the effect and side effects. It
has recently been reported that the use of daily phospho-
diesterase 5 inhibitors can improve not only the sexual
function of patients but also diminishes their urinary
tract symptoms associated with prostate enlargement,
this could be explained by the existence of nitric oxide
receptors in the bladder neck which impact on the re-
laxation resulting in a better micturition (Bittencourt
et al. 2009). Vacuum erection devices and external sup-
port devices cause blood flow to be directed into the
penis, and when a satisfactory erection is obtained, a
compressive device is applied at the base of the penis
in order to prevent a blood return and lose the erec-
tion. Among its limitations is that the penis is cold dueto non-circulating blood, the sensation is diminished
because nerve compression and the uncomfortable
process to obtain the erection. There are few studies
with the use of vacuum erection devices in diabetic pa-
tients, however, it has been reported by ED diabetic pa-
tients that they significantly improved their sexual
intercourse with this device, however, only between 20 to
50% had satisfactory erections (Levine and Dimitriou
2001). The intraurethral suppositories are prostaglandin
E1 suppositories that were injected into the urethra and
distributed along it; however, its use has been limited
because it is not worldwide distributed. It has a reported
efficiency of 60% with diabetic men having a satisfactory
sexual intercourse, although in clinical practice it has
not been as effective (Huang and Lie 2013; Fulgham
et al. 1998).
Prostaglandin E-1 injection directly into the corpus cav-
ernosum has a direct effect on the blood vessels causing
an immediate penile erection, with a reported response
rate of as high as 83%, with a significantly improve in their
sexual function (Heaton et al. 2001). Among its limita-
tions, are the injection prior to each sexual encounter, this
impact on the spontaneity of the relation, and its adverse
effect of penile pain, hematomas, infection, fibrosis and
priapism. Nevertheless, there are reports that there is a
high compliance with patients injecting themselves for up
to 7 continuous years despite the pain associated with its
administration (16 of 18 ED diabetic males compared to 7
out of 22 healthy ED patients) (Perimenis et al. 2001; Basu
and Ryder 2004).
Urinary tract infections
It is well recognized that diabetic patients have a higher
incidence of infections, and the urinary tract (UTI) is
not the exception, with a large variety of infections. DM
is associated with severe cutaneous infections of the gen-
itals such as Fournier’s gangrene, and DM type 1 pa-
tients tend to have a higher incidence of pyelonephritis.
Bacterial cystitis is frequently suffered by diabetic pa-
tients; it is more common in women than in men, espe-
cially in those with type II DM. Diabetic women have a
higher prevalence of asymptomatic bacteriuria than
healthy women, and they have a greater tendency for de-
veloping symptomatic UTI and recurrent complications
with a higher incidence of more serious complications
(Geerlings et al. 2000a,b). Because of the above there is a
tendency towards close screening and treatment of asymp-
tomatic bacteriuria, however it has not been proven to
diminish the number of symptomatic infections or
hospitalizations (Harding et al. 2002).
Hospitalization due to pyelonephritis occurs more fre-
quently in diabetic patients and they are at a higher risk
of developing acute pyelonephritis (sometimes with bi-
lateral renal involvement), which could progress to renal
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nephritis and bacteremia. Pyelonephritis in DM can be
the origin of severe complications that can end up in
organ failure and even death (Stapleton 2002). Because
of the above it is important to be vigilant of the usual
clinical manifestations which include urinary urgency,
frequency, bad odor, pain, tenesm, incomplete emptying
and incontinence.
Despite being E. coli the most frequent bacteria, un-
usual and aggressive pathogens are more prevalent in
DM such as: fungal infections, Klebsiella, gram negative
rods, enterococci, group B streptococci, Pseudomonas
and Proteus mirabilis (Ronald 2002). Premenopausal and
postmenopausal periods double the risk of developing
the UTI. Another risk factor is sexual activity, which is
the most important risk factor in women with type I dia-
betes (Geerlings et al. 2000a,b). Strategies to prevent re-
current UTI are: postcoital antibiotics or prophylactic
antimicrobials taken on a regular basis at bedtime, being
considered trimethoprim, co-trimoxazole, or nitrofuran-
toin as the standard regimens (Grabe et al. 2009). Fi-
nally, it has been observed that diabetic women have up
to four times the risk when they are in oral treatment or
insulin (Boyko et al. 2002).
DM also results in abnormalities in the host defense
system that may result in a higher risk of developing in-
fection. Immunologic impairments such as defective mi-
gration and phagocytes alterations of chemotaxis in
polymorphonuclear leukocytes are well common in dia-
betic patients. However, there is a study of diabetic
women that found no differences in polymorphonuclear
leukocyte function among women with diabetes, com-
pared to healthy individuals (Dalal et al. 2009). Additionally
certain cytokines such as IL-6 and other proinflammatory
cytokines are diminished in the urine in comparison to
women with no diabetes (Caqueiro et al. 2012).
Conclusion
There is worldwide an epidemic of obesity, which in-
creases significantly the number of diabetic patients, and
if we consider that urologic diseases are very prevalent
in the general population, it is very important to know
which are the most frequent association of both, in
order to diagnose them early and keep them in mind
when evaluating these patients.
Even though incontinence and sexual dysfunction does
not cause any life threatening disease, however it does
cause severe discomfort and affects their quality of life.
Because of this it is important to evaluate the sexual
sphere when diabetic patients are treated for any other
disease. The pathophysiology and possible mechanisms
by which DM patients have more urologic complications
are not clear, the genitourinary organs have a multicellu-
lar make it unlikely that a single mechanism underliesboth voiding and sexual dysfunction in diabetes. The
hyperglycemia impact on several levels of nerve, epithe-
lium and mesenchymal components that is why is im-
portant to develop multiple therapeutic classes that may
be relevant during specific phases of diabetes.
A better knowledge of the different influencing factors
will provide a better opportunity to treat these patients.
The common urologic treatments among diabetic pa-
tients should be carefully examined, as this is a disease
that affects many organs at different levels and diabetes
development is related to glycemic control of each indi-
vidual, so it is important to consider the condition of
each patient to select the most appropriate treatment.
It is important to keep in mind these complications in
order to prevent them, diagnose them at early stages and
treat them with an integral perspective of the individual,
in order to offer the patients with DM a better quality
of life.
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